Literature DB >> 10223953

An SHV-derived extended-spectrum beta-lactamase in Pseudomonas aeruginosa.

T Naas1, L Philippon, L Poirel, E Ronco, P Nordmann.   

Abstract

A clinical isolate of Pseudomonas aeruginosa RP-1 produced the extended-spectrum beta-lactamase (ESBL) SHV-2a. Its gene was expressed from a composite promoter made of the -35 region derived from the left inverted repeat of IS26 and the -10 region from the blaSHV-2a promoter itself. The DNA sequences immediately surrounding blaSHV-2a were homologous to plasmid pMPA2a from Klebsiella pneumoniae KpZU-3, while further away and 3' to the blaSHV-2a gene, a sequence corresponding to the left end of Tn1721 was detected, thus indicating a likely enterobacterial origin of this ESBL gene.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10223953      PMCID： PMC89260     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Molecular characterization of a new plasmid-encoded SHV-type beta-lactamase (SHV-2 variant) conferring high-level cefotaxime resistance upon Klebsiella pneumoniae.

Authors:  A Podbielski; J Schönling; B Melzer; K Warnatz; H G Leusch
Journal:  J Gen Microbiol       Date:  1991-03

2.  An IS1-like element is responsible for high-level synthesis of extended-spectrum beta-lactamase TEM-6 in Enterobacteriaceae.

Authors:  S Goussard; W Sougakoff; C Mabilat; A Bauernfeind; P Courvalin
Journal:  J Gen Microbiol       Date:  1991-12

Review 3.  More extended-spectrum beta-lactamases.

Authors:  G A Jacoby; A A Medeiros
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

4.  Nucleotide sequence of IS26, a new prokaryotic mobile genetic element.

Authors:  B Mollet; S Iida; J Shepherd; W Arber
Journal:  Nucleic Acids Res       Date:  1983-09-24       Impact factor: 16.971

5.  Different promoters of SHV-2 and SHV-2a beta-lactamase lead to diverse levels of cefotaxime resistance in their bacterial producers.

Authors:  A Podbielski; J Schönling; B Melzer; G Haase
Journal:  J Gen Microbiol       Date:  1991-07

6.  Heterogeneity of class I beta-lactamase expression in clinical isolates of Pseudomonas aeruginosa.

Authors:  C C Sanders; M L Gates; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

Review 7.  Origin and impact of plasmid-mediated extended-spectrum beta-lactamases.

Authors:  A Philippon; G Arlet; P H Lagrange
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

8.  Sequence analysis of PER-1 extended-spectrum beta-lactamase from Pseudomonas aeruginosa and comparison with class A beta-lactamases.

Authors:  P Nordmann; T Naas
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

9.  Complete nucleotide sequence of Tn1721: gene organization and a novel gene product with features of a chemotaxis protein.

Authors:  H Allmeier; B Cresnar; M Greck; R Schmitt
Journal:  Gene       Date:  1992-02-01       Impact factor: 3.688

10.  Characterization of a novel extended-spectrum beta-lactamase from Pseudomonas aeruginosa.

Authors:  P Nordmann; E Ronco; T Naas; C Duport; Y Michel-Briand; R Labia
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191
View more
  41 in total

Review 1.  Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat.

Authors:  P A Bradford
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Real-time PCR and melting curve analysis for reliable and rapid detection of SHV extended-spectrum beta-lactamases.

Authors:  C C Randegger; H Hächler
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Clinical strain of Pseudomonas aeruginosa carrying a bla(TEM-21) gene located on a chromosomal interrupted TnA type transposon.

Authors:  Véronique Dubois; Corinne Arpin; Patrick Noury; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Detection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes.

Authors:  E Tzelepi; P Giakkoupi; D Sofianou; V Loukova; A Kemeroglou; A Tsakris
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

5.  Survey of plasmid-associated genetic markers in enterobacteriaceae with reduced susceptibilities to cephalosporins.

Authors:  Karen E Preston; Eileen M Graffunder; Ann M Evans; Richard A Venezia
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 6.  Ambler class A extended-spectrum beta-lactamases in Pseudomonas aeruginosa: novel developments and clinical impact.

Authors:  Gerhard F Weldhagen; Laurent Poirel; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

7.  Insertion sequence ISEcp1B is involved in expression and mobilization of a bla(CTX-M) beta-lactamase gene.

Authors:  Laurent Poirel; Jean-Winoc Decousser; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

8.  Association of plasmid-mediated quinolone resistance with extended-spectrum beta-lactamase VEB-1.

Authors:  Laurent Poirel; Marc Van De Loo; Hedi Mammeri; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

9.  Widely distributed and predominant CTX-M extended-spectrum beta-lactamases in Amsterdam, The Netherlands.

Authors:  N al Naiemi; A Bart; M D de Jong; C M Vandenbroucke-Grauls; P J G M Rietra; Y J Debets-Ossenkopp; P C Wever; L Spanjaard; A J Bos; B Duim
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

10.  Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada.

Authors:  David A Boyd; Shaun Tyler; Sara Christianson; Allison McGeer; Matthew P Muller; Barbara M Willey; Elizabeth Bryce; Michael Gardam; Patrice Nordmann; Michael R Mulvey
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.